QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases
QYNAPSE SAS, a French medical technology company, today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the work of Prof. Simon Duchesne at the CERVO Brain Research Center and Université Laval and Prof. Louis Collins at the Montreal Neurological Institute and McGill University. TPMD, which was supported by SOVAR in its early days, designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases. The Company’s lead product is an innovative software-as-a-service web-enabled solution, which allows specialists to analyze magnetic resonance images in a convenient and cost-effective manner. Within the Alzheimer’s disease primary market, the analysis provides crucial information to not only make more definitive diagnoses, but to accurately predict the rate of disease progression in pre-demented subjects.
The objective of this strategic collaboration is to combine TPMD's technologies, patents and expertize with Qynapse's know-how and product line – and thus form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer's, Parkinson's and multiple sclerosis.
SOVAR would like to highlight this unique technological alliance to improve the performance of clinical trials and the personalization of the management of brain diseases. Another great example that Canadian technology is advancing AI in health for the benefit of the patient.
Read the official press release here.